These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 35320355)

  • 1. Differential Gain-of-Function Activity of Three p53 Hotspot Mutants In Vivo.
    Xiong S; Chachad D; Zhang Y; Gencel-Augusto J; Sirito M; Pant V; Yang P; Sun C; Chau G; Qi Y; Su X; Whitley EM; El-Naggar AK; Lozano G
    Cancer Res; 2022 May; 82(10):1926-1936. PubMed ID: 35320355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants.
    Chachad D; Patel LR; Recio CV; Pourebrahim R; Whitley EM; Wang W; Su X; Xu A; Lee DF; Lozano G
    Cancer Res; 2023 Jul; 83(14):2297-2311. PubMed ID: 37205631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gain-of-function mutant p53 promotes the oncogenic potential of head and neck squamous cell carcinoma cells by targeting the transcription factors FOXO3a and FOXM1.
    Tanaka N; Zhao M; Tang L; Patel AA; Xi Q; Van HT; Takahashi H; Osman AA; Zhang J; Wang J; Myers JN; Zhou G
    Oncogene; 2018 Mar; 37(10):1279-1292. PubMed ID: 29269868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 loss-of-heterozygosity is a necessary prerequisite for mutant p53 stabilization and gain-of-function in vivo.
    Alexandrova EM; Mirza SA; Xu S; Schulz-Heddergott R; Marchenko ND; Moll UM
    Cell Death Dis; 2017 Mar; 8(3):e2661. PubMed ID: 28277540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis.
    Hanel W; Marchenko N; Xu S; Yu SX; Weng W; Moll U
    Cell Death Differ; 2013 Jul; 20(7):898-909. PubMed ID: 23538418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trp53 null and R270H mutant alleles have comparable effects in regulating invasion, metastasis, and gene expression in mouse colon tumorigenesis.
    Tang J; Feng Y; Kuick R; Green M; Green M; Sakamoto N; Kurosu Y; Lin J; Cho KR; Fearon ER
    Lab Invest; 2019 Oct; 99(10):1454-1469. PubMed ID: 31148594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of wild-type p53 promotes mutant p53-driven metastasis through acquisition of survival and tumor-initiating properties.
    Nakayama M; Hong CP; Oshima H; Sakai E; Kim SJ; Oshima M
    Nat Commun; 2020 May; 11(1):2333. PubMed ID: 32393735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional studies of a novel germline p53 splicing mutation identified in a patient with Li-Fraumeni-like syndrome.
    Piao J; Sakurai N; Iwamoto S; Nishioka J; Nakatani K; Komada Y; Mizutani S; Takagi M
    Mol Carcinog; 2013 Oct; 52(10):770-6. PubMed ID: 22495821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrative genome analysis of somatic p53 mutant osteosarcomas identifies Ets2-dependent regulation of small nucleolar RNAs by mutant p53 protein.
    Pourebrahim R; Zhang Y; Liu B; Gao R; Xiong S; Lin PP; McArthur MJ; Ostrowski MC; Lozano G
    Genes Dev; 2017 Sep; 31(18):1847-1857. PubMed ID: 29021240
    [No Abstract]   [Full Text] [Related]  

  • 10. S100a4 upregulation in Pik3caH1047R;Trp53R270H;MMTV-Cre-driven mammary tumors promotes metastasis.
    Yuan W; Goldstein LD; Durinck S; Chen YJ; Nguyen TT; Kljavin NM; Sokol ES; Stawiski EW; Haley B; Ziai J; Modrusan Z; Seshagiri S
    Breast Cancer Res; 2019 Dec; 21(1):152. PubMed ID: 31881983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gain-of-Function p53 Mutation Acts as a Genetic Switch for TGFβ Signaling-Induced Epithelial-to-Mesenchymal Transition in Intestinal Tumors.
    Wang D; Nakayama M; Hong CP; Oshima H; Oshima M
    Cancer Res; 2024 Jan; 84(1):56-68. PubMed ID: 37851521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53R245W Mutation Fuels Cancer Initiation and Metastases in NASH-driven Liver Tumorigenesis.
    Dibra D; Gagea M; Qi Y; Chau GP; Su X; Lozano G
    Cancer Res Commun; 2023 Dec; 3(12):2640-2652. PubMed ID: 38047594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pla2g16 phospholipase mediates gain-of-function activities of mutant p53.
    Xiong S; Tu H; Kollareddy M; Pant V; Li Q; Zhang Y; Jackson JG; Suh YA; Elizondo-Fraire AC; Yang P; Chau G; Tashakori M; Wasylishen AR; Ju Z; Solomon H; Rotter V; Liu B; El-Naggar AK; Donehower LA; Martinez LA; Lozano G
    Proc Natl Acad Sci U S A; 2014 Jul; 111(30):11145-50. PubMed ID: 25024203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 mutant-type in human prostate cancer cells determines the sensitivity to phenethyl isothiocyanate induced growth inhibition.
    Aggarwal M; Saxena R; Asif N; Sinclair E; Tan J; Cruz I; Berry D; Kallakury B; Pham Q; Wang TTY; Chung FL
    J Exp Clin Cancer Res; 2019 Jul; 38(1):307. PubMed ID: 31307507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ets2 anchors the prometastatic function of mutant p53 in osteosarcoma.
    Liu DD; Kang Y
    Genes Dev; 2017 Sep; 31(18):1823-1824. PubMed ID: 29051386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterogeneity of Li-Fraumeni syndrome links to unequal gain-of-function effects of p53 mutations.
    Xu J; Qian J; Hu Y; Wang J; Zhou X; Chen H; Fang JY
    Sci Rep; 2014 Feb; 4():4223. PubMed ID: 24573247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance.
    Stiewe T; Haran TE
    Drug Resist Updat; 2018 May; 38():27-43. PubMed ID: 29857816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The lung-enriched p53 mutants V157F and R158L/P regulate a gain of function transcriptome in lung cancer.
    Barta JA; Pauley K; Kossenkov AV; McMahon SB
    Carcinogenesis; 2020 Mar; 41(1):67-77. PubMed ID: 31067569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutant p53: it's not all one and the same.
    Kennedy MC; Lowe SW
    Cell Death Differ; 2022 May; 29(5):983-987. PubMed ID: 35361963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of glucosylceramide synthase eliminates the oncogenic function of p53 R273H mutant in the epithelial-mesenchymal transition and induced pluripotency of colon cancer cells.
    Hosain SB; Khiste SK; Uddin MB; Vorubindi V; Ingram C; Zhang S; Hill RA; Gu X; Liu YY
    Oncotarget; 2016 Sep; 7(37):60575-60592. PubMed ID: 27517620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.